Neurosense Therapeutics Stock Forward View - Triple Exponential Smoothing
| NRSN Stock | USD 0.79 -0.0024 -0.30% |
This page provides reference data for Neurosense Therapeutics using Triple Exponential Smoothing forecasting. The projected value and error metrics are calculated from available daily price observations.
The Triple Exponential Smoothing forecasted value of Neurosense Therapeutics on the next trading day is expected to be 0.79 with a mean absolute deviation of 0.04 and the sum of the absolute errors of 2.21.As with simple exponential smoothing, in triple exponential smoothing models past Neurosense Therapeutics observations are given exponentially smaller weights as the observations get older. In other words, recent observations are given relatively more weight in forecasting than the older Neurosense Therapeutics observations. This Triple Exponential Smoothing reference page for Neurosense Therapeutics presents model-generated projections from historical price data for informational purposes. Triple Exponential Smoothing Price Forecast For the 21st of March
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of Neurosense Therapeutics on the next trading day is expected to be 0.79 with a mean absolute deviation of 0.04 , mean absolute percentage error of 0.0024 , and the sum of the absolute errors of 2.21 .Please note that although there have been many attempts to predict Neurosense Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Neurosense Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Neurosense Therapeutics | Neurosense Therapeutics Price Prediction | Research Analysis |
Forecasted Value
For the next trading day, Macroaxis evaluates Neurosense Therapeutics' predictive range by looking for statistically meaningful downside and upside boundaries. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Neurosense Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Neurosense Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | 9.0E-4 |
| MAD | Mean absolute deviation | 0.0375 |
| MAPE | Mean absolute percentage error | 0.0416 |
| SAE | Sum of the absolute errors | 2.2124 |
Other Forecasting Options for Neurosense Therapeutics
For investors considering Neurosense, Neurosense Therapeutics' price movement is the most direct driver of investment returns. Noise in Neurosense Stock price charts can make identifying meaningful trends difficult without dedicated analytical tools.Neurosense Therapeutics Related Equities
The following equities are related to Neurosense Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Neurosense Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Neurosense Therapeutics Market Strength Events
Market strength indicators for Neurosense Therapeutics provide investors with a view of how the stock performs across different market environments. By analyzing these indicators, traders can determine the best moments to enter or exit positions in Neurosense Therapeutics.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.79 | |||
| Day Typical Price | 0.79 | |||
| Price Action Indicator | -0.0036 | |||
| Period Momentum Indicator | -0.0024 | |||
| Relative Strength Index | 44.96 |
Neurosense Therapeutics Risk Indicators
A structured analysis of Neurosense Therapeutics' risk indicators is one of the most reliable ways to improve the accuracy of price forecasts. Understanding the risk embedded in Neurosense Therapeutics' allows investors to decide whether to accept, reduce, or hedge their exposure.
| Mean Deviation | 3.96 | |||
| Standard Deviation | 5.21 | |||
| Variance | 27.19 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Neurosense Therapeutics
The amount of media and story coverage tied to Neurosense Therapeutics can signal where market attention is concentrating at the moment. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Neurosense Therapeutics Short Properties
Reviewing short-oriented indicators for Neurosense Therapeutics is useful because long and short participants often create very different signals for timing and volatility. This is most valuable when investors want to know whether bearish pressure is starting to shape the market's reaction function.
| Common Stock Shares Outstanding | 18.6 M | |
| Cash And Short Term Investments | 3.4 M |